Clinical Trials
9 trialsNCT05072106 2025-09-16
Study to Evaluate the Effect of Bosentan on the Pharmacokinetics of Lurbinectedin in Patients With Advanced Solid Tumors
PharmaMar
Phase 1 Completed
NCT05063318 2025-09-02
Clinical Trial of Lurbinectedin (PM01183) in Patients With Advanced Solid Tumors
PharmaMar
Phase 1 Completed
NCT02611024 2025-07-09
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
PharmaMar
Phase 1/2 Completed
NCT04638491 2024-06-10
Safety Tolerability Pharmacokinetic and Preliminary Efficacy in Chinese Advanced Solid Tumors Patients
Luye Pharma Group Ltd.
Phase 1 Completed
NCT05101265 2023-11-27
Clinical Pharmacokinetic Study of Lurbinectedin in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Impairment
PharmaMar
Phase 1 Unknown
NCT02454972 2023-03-02
Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors
PharmaMar
Phase 2 Completed
NCT02451007 2019-11-19
Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization in Patients With Selected Solid Tumors
PharmaMar
Phase 2 Completed
NCT01405391 2016-01-15
Study of PM01183 in Non-Colorectal Cancer Patients as a Days 1 and 8 Intravenous Short Infusion Every 3 Weeks
PharmaMar
Phase 1 Completed
NCT00877474 2015-11-04
Phase I, Multicenter, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM01183 in Patients With Advanced Solid Tumors
PharmaMar
Phase 1 Completed